Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

PPHMD

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Peregrine Pharmaceuticals Inc. (MM)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PPHMD
FechaHoraFuenteTítuloSímboloCompañía
29/03/201917:42Business WireAnnouncing VanEck Vectors ETFs’ March 2019 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
26/12/201817:37Business WireAnnouncing VanEck Vectors Equity ETFs December 2018 DistributionNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
17/10/201810:48Business WireVanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports IndustryNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
28/09/201817:03Business WireAnnouncing VanEck Vectors Equity ETFs’ September 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
29/06/201817:15Business WireAnnouncing VanEck Vectors Equity ETFs June 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
29/03/201816:58Business WireAnnouncing VanEck Vectors Equity ETFs March 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
10/11/200908:30PR Newswire (US)New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain CancNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
04/11/200913:17PR Newswire (US)Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting AntibodiesNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
03/11/200914:00PR Newswire (US)Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing RequirementsNASDAQ:PPHMD
27/10/200907:17Edgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
23/10/200916:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
21/10/200908:30PR Newswire (US)Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast CancerNASDAQ:PPHMD
19/10/200908:30PR Newswire (US)Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory AffairsNASDAQ:PPHMD
19/10/200907:30PR Newswire (US)Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes EffectNASDAQ:PPHMD
 Showing the most relevant articles for your search:NASDAQ:PPHMD